Explore findings from a Phase 2a trial evaluating the safety and efficacy of reproxalap, a novel reactive aldehyde species inhibitor, in treating dry eye disease.
RASP inhibitor
Staff Writer
World Eyecare Foundation staff writers are experienced eye care providers, researchers, academicians, industry leaders and practicing ophthalmologists and optometrist from around the world. Content may be generated by AI and is reviewed by the editorial team and specialists in the areas of publications.
World Eye Health Foundation’s mission is to help billions of people around the world to maintain healthy eyes.
© 2023 - 2024 World Eye Health Foundation • Privacy Policy • All Rights Reserved
